Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
NEJM Evidence|February 6, 2024
Intraperitoneal Therapy for Ovarian Cancer - Some Answers, More Questions, and Missed OpportunitiesOladapo O YekuBiochemical Society Transactions|April 13, 2016
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacyOladapo O Yeku, Renier J BrentjensScientific Reports|September 7, 2017
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironmentOladapo O Yeku, Terence J Purdon, Mythili Koneru, et al.International Journal of Molecular Sciences|January 28, 2026
Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer TherapyAdam P Jones, Yanxia Zhao, Bo R Rueda, et al.Nature Reviews. Clinical Oncology|June 17, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challengesKathleen N Moore, Oladapo O Yeku, Brooke E Howitt, et al.Frontiers in Pharmacology|December 22, 2025
CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancerRaj Kumar, Irva E Veillard, Mengyao Xu, et al.Reproductive Sciences (Thousand Oaks, Calif.)|April 24, 2024
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment OptionsYusuke Matoba, Kyle M Devins, Lara Milane, et al.Journal of Ovarian Research|February 19, 2024
Structural basis for antibody recognition of the proximal MUC16 ectodomainKwangkook Lee, Kay Perry, Mengyao Xu, et al.Frontiers in Immunology|May 3, 2021
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF InhibitionOladapo O Yeku, Thapi Dharma Rao, Ian Laster, et al.American Journal of Clinical Oncology|November 24, 2021
Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal BrachytherapyAndrea L Russo, Larissa J Lee, Jennifer Y Wo, et al.Pageof 2